CCP
NVS icon

Corient Capital Partners’s Novartis NVS Stock Holding History

Corient Capital Partners’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$482K Buy
5,708
+316
+6% +$26.2K 0.04% 347
2022
Q2 		$455K Sell
5,392
-242
-4% -$21.2K 0.03% 367
2022
Q1 		$494K Buy
5,634
+1,443
+34% +$125K 0.03% 392
2021
Q4 		$366K Sell
4,191
-6,837
-62% -$568K 0.02% 454
2021
Q3 		$902K Buy
11,028
+432
+4% +$38.9K 0.07% 229
2021
Q2 		$967K Buy
10,596
+1,344
+15% +$120K 0.07% 219
2021
Q1 		$791K Buy
9,252
+833
+10% +$74.8K 0.07% 229
2020
Q4 		$795K Sell
8,419
-3,202
-28% -$280K 0.08% 203
2020
Q3 		$1.01M Buy
11,621
+225
+2% +$19.5K 0.12% 162
2020
Q2 		$995K Buy
11,396
+67
+0.6% +$5.78K 0.12% 157
2020
Q1 		$934K Sell
11,329
-4,297
-27% -$383K 0.15% 130
2019
Q4 		$1.48M Sell
15,626
-592
-4% -$53.1K 0.19% 123
2019
Q3 		$1.41M Sell
16,218
-921
-5% -$82.7K 0.2% 125
2019
Q2 		$1.56M Sell
17,139
-2,465
-13% -$209K 0.24% 108
2019
Q1 		$1.69M Sell
19,604
-598
-3% -$48K 0.27% 106
2018
Q4 		$1.55M Buy
20,202
+1,520
+8% +$118K 0.28% 106
2018
Q3 		$1.44M Hold
18,682
– – 0.24% 120
2018
Q2 		$1.26M Buy
18,682
+2,301
+14% +$159K 0.22% 131
2018
Q1 		$1.19M Buy
16,381
+4,535
+38% +$345K 0.22% 114
2017
Q4 		$891K Sell
11,846
-876
-7% -$66.1K 0.15% 142
2017
Q3 		$979K Sell
12,722
-233
-2% -$17.6K 0.19% 122
2017
Q2 		$969K Buy
12,955
+334
+3% +$23.7K 0.15% 140
2017
Q1 		$840K Buy
12,621
+2,030
+19% +$135K 0.13% 154
2016
Q4 		$691K Sell
10,591
-1,493
-12% -$96.8K 0.12% 168
2016
Q3 		$855K Buy
+12,084
New +$881K 0.16% 139

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Corient Capital Partners's NVS Position: Q3 2022 in Review

Corient Capital Partners increased its Novartis (NVS) stake by 5.9% in Q3 2022, buying an estimated $26.2K and bringing the position to 5,708 shares worth $482K. The position accounts for 0.04% of the portfolio, ranked #347.

Corient Capital Partners first reported a position in NVS in Q3 2016 and has held it in 25 quarters since. The position peaked at $1.69M in Q1 2019. 1,088 funds tracked by Wall St. Rank hold NVS as of Q3 2022.

  • Corient Capital Partners held 5,708 shares of Novartis worth $482K as of Q3 2022.
  • Corient Capital Partners bought 316 Novartis shares in Q3 2022, an estimated $26.2K.
  • Novartis made up 0.04% of Corient Capital Partners's portfolio in Q3 2022, its #347 holding.
  • Corient Capital Partners first reported a position in Novartis in Q3 2016 and has held it in 25 quarters since.
  • Corient Capital Partners's Novartis position peaked at $1.69M in Q1 2019.
  • 1,088 funds tracked by Wall St. Rank held Novartis as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.